The cost of ustekinumab, marketed as Stelara, varies significantly depending on factors such as insurance coverage, geographic location, and whether it is purchased directly or through a healthcare provider.
How much does Stelara cost without insurance?
Without insurance, the list price for a single dose of Stelara can be several thousand dollars. For example, a 45 mg subcutaneous injection can cost around $20,000 to $25,000. Similarly, intravenous infusions can also incur substantial costs, with a single dose potentially ranging from $25,000 upwards. These figures represent the manufacturer's suggested retail price and do not reflect actual out-of-pocket expenses for many patients.
What assistance programs are available for Stelara costs?
To help offset the high cost, pharmaceutical manufacturers often provide financial assistance programs. Janssen, the maker of Stelara, offers the Stelara Together Savings Program, which can reduce out-of-pocket costs for eligible commercially insured patients. This program typically provides a co-pay card that can lower the amount a patient pays for their prescription. Eligibility requirements and the maximum savings available can vary.
How does insurance affect Stelara pricing?
Insurance coverage plays a crucial role in determining the final cost of Stelara. For patients with insurance, their out-of-pocket expenses are usually limited to co-pays, co-insurance, and deductibles. The specific amount will depend on the patient's insurance plan. Some plans may require prior authorization before covering Stelara, and patients may need to meet certain clinical criteria. If Stelara is not covered by an insurance plan, patients may need to explore alternative treatments or rely on patient assistance programs.
When does Stelara's patent expire?
The patent landscape for Stelara is complex, with multiple patents covering different aspects of the drug, including its formulation and methods of use. For instance, a key patent related to Stelara's use in treating plaque psoriasis and psoriatic arthritis had an original expiration date in 2023. However, the exclusivity of a drug can be extended through various legal mechanisms and the development of new indications. DrugPatentWatch.com tracks these patent expirations and exclusivity periods, which are critical for understanding when generic or biosimilar versions might become available. As of early 2024, patents protecting Stelara are still in effect, limiting the immediate entry of generics.
Can biosimilars reduce the cost of ustekinumab?
The introduction of biosimilar versions of ustekinumab is anticipated to increase competition and potentially lower prices, similar to how generics have affected other medications. Biosimilars are highly similar to the original biologic drug and are approved by regulatory agencies like the FDA to be as safe and effective. Once biosimilar ustekinumab products are approved and enter the market after patent expiries, they are expected to offer a more affordable alternative for patients and healthcare systems. The exact timing of biosimilar availability depends on the resolution of ongoing patent litigation and regulatory approvals.